Showing results (21-30 of 97) with videos related to

Sort By:
Pageof 10
Neurology(R) Neuroimmunology & Neuroinflammation|July 29, 2021
Impact of Disease-Modifying Treatments of Multiple Sclerosis on Anti-SARS-CoV-2 Antibodies: An Observational StudyKévin Bigaut, Laurent Kremer, Thibaut Fabacher, et al.
Multiple Sclerosis and Related Disorders|September 27, 2025
Evolution of high-efficacy treatment strategy for relapsing-remitting multiple sclerosis: A real-life observational studyJudicaelle Didierjean, Laurent Kremer, Livia Lanotte, et al.
Neurology and Therapy|June 5, 2026
A Qualitative Study of Lived Treatment Experiences and Preferences of Long-Term DMT Users with Relapsing-Remitting Multiple SclerosisClair-Antoine Veyrier, Patrick Vermersch, Olivier Casez, et al.
Clinical & Developmental Immunology|May 28, 2013
Evaluation of clinical interest of anti-aquaporin-4 autoantibody followup in neuromyelitis opticaJean-Baptiste Chanson, Melissa Alame, Nicolas Collongues, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|March 4, 2024
Efficacy of dalfampridine in neuromyelitis optica spectrum disorder: A pilot studyJérôme de Seze, Christine Clerc, Matthieu Béreau, et al.
Journal of Neurology|March 27, 2015
Dalfampridine in hereditary spastic paraplegia: a prospective, open studyMatthieu Béreau, Mathieu Anheim, Jean-Baptiste Chanson, et al.
Journal of Neurology|January 4, 2022
Ocrelizumab versus fingolimod after natalizumab cessation in multiple sclerosis: an observational studyKévin Bigaut, Laurent Kremer, Thibaut Fabacher, et al.
Biochimica Et Biophysica Acta. Molecular Basis of Disease|September 14, 2017
The translocator protein ligand XBD173 improves clinical symptoms and neuropathological markers in the SJL/J mouse model of multiple sclerosisGéraldine Leva, Christian Klein, Jérémie Benyounes, et al.
Pageof 10